FORM 7  
  
MONTHLY PROGRESS REPORT

Name of Listed Issuer: ***Telescope Innovations Corp.*** (the “Issuer”).

Trading Symbol: ***TELI***

Number of Outstanding Listed Securities: ***48,786,070 common shares***

Date: ***August 5, 2022***

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

***The Issuer is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Issuer builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. A key area of application for these tools is the development of scalable manufacturing processes for mental health medicines in the under-utilized tryptamine class of compounds, including psychedelic therapeutics. The Issuer also applies these toolsets to resolve inefficiencies in industrial process chemistry and manufacturing. It’s aim is to bring modern chemical solutions to meet the most serious challenges in health and sustainability****.*

1. Provide a general overview and discussion of the activities of management.

***The Issuer signed a Master Service Agreement ("MSA") with Standard Lithium Ltd. ("SLI"). For the first project under this MSA, the Issuer will receive funding for one year to evaluate the utilization and sequestration of CO2 within the lithium brine extraction and reinjection processes developed by SLI. This project bolsters the Issuer's "Industries" division, which leverages unique lab automation and analytical capabilities to address process and manufacturing challenges in the chemical industry.***

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
2. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

***Not applicable***

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

***Standard Lithium Ltd. (SLI) is an innovative technology and lithium development company. SLI's flagship project is located in southern Arkansas, where it is engaged in testing and proving the commercial viability of lithium extraction from over 150,000 acres of permitted brine operations. The president of SLI, Dr. Andy Robinson, and the CEO, Robert Mintak, are also independent directors of the Issuer. However, the MSA is not considered a related party transaction within the meaning of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions, and has been reviewed and approved by Telescope's independent directors.***

Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

***Not applicable***

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

***Not applicable***

1. Describe the acquisition of new customers or loss of customers.

***Not applicable***

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

***Not applicable***

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

***Not applicable***

1. Report on any labour disputes and resolutions of those disputes if applicable.

***Not applicable***

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

***Not applicable***

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

***Not applicable***

1. Provide details of any securities issued and options or warrants granted.

***The Issuer granted a total of 500,000 incentive stock options to certain consultants and advisory board members of the Company in accordance with the Company’s incentive stock option plan. The options vest on November 20, 2022 and are exercisable to acquire common shares of the Company at a price of $0.35 until July 19, 2027.***

1. Provide details of any loans to or by Related Persons.

***Not applicable***

1. Provide details of any changes in directors, officers or committee members.

***Not applicable.***

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

***No trends impacting during July 2022.***

**Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: August 5, 2022

Jason Hein   
Name of Director or Senior Officer

/s/ “Jason Hein”   
Signature

Chief Executive Officer   
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details***  Name of Issuer Telescope Innovations Corp. | For Month Ended July 31, 2022 | Date of Report  YY/MM/DD  2022/8/5 |
| Issuer Address 1600 - 609 Granville Street | | |
| City/Province/Postal Code  Vancouver, British Columbia, V7Y 1C3 | Issuer Fax No.  ( ) | Issuer Telephone No.  ( ) |
| Contact Name  Jason Hein | Contact Position  CEO | Contact Telephone No.  604-960-1189 |
| Contact Email Address  jason@telescopeinn.com | Web Site Address  N/A | |